US2017267784A1PendingUtilityA1

Single domain antibodies directed against intracellular antigens

50
Assignee: SINGH MOLECULAR MEDICINE LLCPriority: Oct 23, 2014Filed: May 30, 2017Published: Sep 21, 2017
Est. expiryOct 23, 2034(~8.2 yrs left)· nominal 20-yr term from priority
Inventors:Sunanda Singh
C12N 15/00A61K 2039/505C07K 16/18G01N 33/6854C07K 2317/569C07K 16/241A61K 39/39558C07K 16/3015A61K 45/06C07K 2317/80C07K 2317/76C07K 2317/22C07K 16/32G01N 33/6872C12Q 1/68C07K 2317/92C07K 16/468A61K 39/00A61K 39/395
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention provides compositions and methods to treat a condition or disease without the use of exogenous targeting sequences or chemical compositions. The present invention relates to single-domain antibodies (sdAbs), proteins and polypeptides comprising the sdAbs that are directed against intracellular components that cause a condition or disease. The invention also includes nucleic acids encoding the sdAbs, proteins and polypeptides, and compositions comprising the sdAbs. The invention includes the use of the compositions, sdAbs, and nucleic acids encoding the sdAbs for prophylactic, therapeutic or diagnostic purposes.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A single-domain antibody (sdAb) directed against an intracellular component, wherein the sdAB can passively cross a cellular membrane to target the intracellular component without exogenous compounds and without additional membrane targeting sequences. 
     
     
         2 . The sdAb of  claim 1 , wherein the intracellular component comprises a nucleic acid, protein, lipid, carbohydrate, or combination thereof. 
     
     
         3 . The sdAb of  claim 1 , wherein the intracellular component comprises a protein. 
     
     
         4 . The sdAb of  claim 3 , wherein the protein is un-phosphorylated. 
     
     
         5 . The sdAb of  claim 3 , wherein the protein is phosphorylated. 
     
     
         6 . The sdAb of  claim 1 , wherein the intracellular component comprises a STAT protein. 
     
     
         7 . The sdAb of  claim 6 , wherein the STAT protein comprises STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, or STAT6. 
     
     
         8 . The sdAb of  claim 1 , wherein the sdAb is multispecific for two or more antigens. 
     
     
         9 . A method of treating a disease, preventing a disease or preventing the reoccurrence of a disease in a subject using the sdAb of  claim 1 . 
     
     
         10 . The method of  claim 9 , wherein the sdAb can be used to deliver a therapeutic agent. 
     
     
         11 . The method of  claim 10 , wherein the sdAb can be used to deliver the therapeutic agent across the blood-brain barrier to an individual in need thereof. 
     
     
         12 . The method of  claim 9 , wherein the sdAb is used in combination with one or more compounds. 
     
     
         13 . The method of  claim 12 , wherein the one or more compounds is a transcriptional inhibitor. 
     
     
         14 . A single-domain antibody (sdAb) directed against an intracellular component, wherein the sdAB can passively cross blood-brain barrier to target the intracellular component without exogenous compounds and without additional membrane targeting sequences. 
     
     
         15 . The sdAb of  claim 14 , wherein the intracellular component comprises a nucleic acid, protein, lipid, carbohydrate, or combination thereof. 
     
     
         16 . The sdAb of  claim 14 , wherein the intracellular component comprises a protein. 
     
     
         17 . The sdAb of  claim 16 , wherein the protein is un-phosphorylated. 
     
     
         18 . The sdAb of  claim 16 , wherein the protein is phosphorylated. 
     
     
         19 . The sdAb of  claim 14 , wherein the intracellular component comprises a STAT protein. 
     
     
         20 . The sdAb of  claim 19 , wherein the STAT protein comprises STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, or STAT6. 
     
     
         21 . The sdAb of  claim 14 , wherein the sdAb is multispecific for two or more antigens. 
     
     
         22 . A method of treating a disease, preventing a disease or preventing the reoccurrence of a disease in a subject using the sdAb of  claim 14 . 
     
     
         23 . The method of  claim 22 , wherein the sdAb can be used to deliver a therapeutic agent to an individual in need thereof. 
     
     
         24 . The method of  claim 22 , wherein the sdAb is used in combination with one or more compounds. 
     
     
         25 . The method of  claim 22 , wherein the one or more compounds is a transcriptional inhibitor.

Join the waitlist — get patent alerts

Track US2017267784A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.